LCN2 and Alzheimer disease: A recent study found that the iron chelators deferoxamine and deferiprone reduce Aβ-induced iron accumulation in astrocytes and inhibit Aβ-induced Lcn2, suggesting these molecules as promising therapeutic strategies against AD [205].